Unlocking the Mystery of HLH: How to Spot This Rare But Deadly Condition
"A deep dive into hemophagocytic lymphohistiocytosis (HLH) secondary to Epstein-Barr virus, its symptoms, and why early treatment is crucial."
Most primary Epstein-Barr virus (EBV) infections are so mild they go unnoticed. When EBV does cause noticeable symptoms, it usually manifests as infectious mononucleosis (mono). While mono typically resolves on its own, in rare cases, it can lead to severe complications, including lymphoproliferative disorders like hemophagocytic lymphohistiocytosis (HLH). HLH is a serious condition characterized by an overactive immune response.
This article delves into a case of HLH triggered by EBV that unfortunately had a fatal outcome, highlighting the aggressive nature and potential challenges in managing this condition.
The original research recounts the experience of a 26-year-old male, with no significant prior medical history, who sought emergency care due to abdominal pain, vomiting, diarrhea, and a fever reaching 40°C (104°F). Upon examination, doctors noted an enlarged spleen and swollen inguinal lymph nodes. Initial lab work revealed elevated bilirubin, liver enzymes (GPT/GOT/GGT), alkaline phosphatase, LDH, ferritin, and C-reactive protein (CRP), along with decreased white blood cell count (leukocytes), low hematocrit, and reduced platelet count.
A Rare but Unevenly Distributed Condition
Primary HLH is reported at approximately 1 in 50,000, with more than 90% of cases manifesting within the first two years of life and 70% to 80% occurring within that period. At UCLA Medical Center, the rate of Epstein-Barr virus-associated HLH rose from 0.14 per 10,000 hospital discharges during 2007–2009 to 4.9 per 10,000 in 2010. In a 2025 case–control analysis, EBV infection occurred in 34 of 48 pediatric HLH cases, or 70.8%, a significantly higher proportion than infections caused by other pathogens.
Diagnosis and Treatment Are Clinically Complex
HLH should be suspected in patients with varied hyperinflammatory clinical presentations, according to a clinical review. EBV is described as the most frequent infection associated with HLH, but EBV-associated disease can range from inflammation that resolves spontaneously to unrelenting illness. This broad clinical spectrum makes recognition and management challenging, particularly when the presentation resembles other inflammatory conditions.
EBV-HLH Has Expanded Beyond Traditional Expectations
Recent reporting indicates that EBV-associated HLH can develop from latent EBV infection in immunocompetent adults without a history of chronic active EBV disease or EBV-associated malignancy. Earlier clinical reports documented fatal EBV-related HLH, including a 24-year-old woman with fever of unknown origin. Another report described a six-year-old boy with previous Burkitt-type B-cell non-Hodgkin lymphoma who developed high fevers and hepatosplenomegaly after EBV-triggered HLH.
Decoding HLH: Symptoms, Diagnosis, and the Race Against Time
The patient's condition continued to deteriorate, marked by persistent fever, worsening liver function (indicated by both cytolysis and cholestasis patterns), and a further drop in blood cell counts. Immature blood cells began appearing in the peripheral blood, adding to the concern. A CT scan of the abdomen revealed an enlarged liver and spleen, accompanied by multiple enlarged lymph nodes in the retroperitoneal, iliac, and inguinal regions, raising suspicion for a myeloproliferative disorder.
- Key Indicators: The patient's case underscores the importance of recognizing the signs and symptoms of HLH, particularly in the context of an EBV infection.
- Fever: Persistent high fever (above 38°C / 100.4°F).
- Enlarged organs: Hepatosplenomegaly (enlarged liver and spleen).
- Blood abnormalities: Pancytopenia (low counts of red blood cells, white blood cells, and platelets), elevated ferritin, hypertriglyceridemia, and hypofibrinogenemia.
- Liver Dysfunction: Abnormal liver function tests.
Research Focuses on Diagnosis, Biomarkers, and Triggers
A review by Imashuku described diagnostic problems, clinical and histopathological features, and treatment strategies for EBV-associated HLH. More recent research emphasizes that acute EBV infection can occasionally precipitate the severe syndrome known as EBV-HLH. Clinical summaries also identify infection, malignancy, and autoimmune disorders as causes of secondary HLH, with EBV among the infections associated with it.
Rare Complications Can Be Overlooked
A reported fatal complication involves chronic active EBV infection occurring together with HLH and B- or NK/T-cell lymphoma. The report characterizes this combination as rare and potentially underestimated. Its findings underscore that persistent or severe EBV-related illness may involve more than an isolated inflammatory episode.
EBV-HLH Can Mimic Malignancy
EBV-associated HLH may mimic T-cell lymphoma, and the CDC review states that it is treated with cytotoxic chemotherapy. Hemophagocytic syndromes associated with nonviral causes are discussed separately, indicating that the infectious trigger can influence clinical interpretation and treatment framing. In childhood, EBV-HLH is described as the most common cause of secondary hemophagocytic disease, while EBER-positive small T cells may also be seen in bone marrow.
The Urgency of Early Action in HLH
This tragic case highlights several key aspects of HLH: its potential to arise from common infections like EBV, its aggressive nature, and the critical importance of early diagnosis and treatment. HLH is characterized by an excessive immune response, leading to widespread inflammation and organ damage. The condition can be triggered by genetic factors or secondary to infections, with EBV being a prominent culprit.
EBV-Related HLH Can Deteriorate Quickly
A Massachusetts General Hospital case record described a 71-year-old man who presented with loss of consciousness after gait changes, intermittent fevers, and fatigue. The case illustrates how EBV-associated HLH may come to medical attention through neurological deterioration after nonspecific symptoms. In rheumatic disease-associated HLH, the cited report characterizes the condition as lethal and identifies EBV infection as a relevant factor.
Treatment Development Remains an Open Frontier
A market analysis expects the hemophagocytic lymphohistiocytosis market to grow by 2036 and notes clinically diagnosed HIV, EBV, or CMV infection in the disease context. The Histiocytosis Association reports that HLH was once thought to affect only young infants and children but is increasingly recognized more broadly. Together, these sources point to continuing attention to diagnosis, patient populations, and treatment needs across age groups.
Chronic Active EBV Adds Long-Term Risk
Systemic chronic active EBV disease is described as a rare, delayed, and life-threatening complication of EBV infection. EBV-HLH also presents a clinical conundrum because only a minority of patients achieve long-standing clinical remission with front-line treatment, according to the cited Blood commentary. These observations highlight the difficulty of managing disease that may be delayed, severe, and resistant to durable control.
Newer Therapies Show Early Promise
A 2026 exploratory study examined PD-1 inhibitors used alone or combined with ruxolitinib for adult EBV-HLH. The study reported preliminary favorable efficacy and high tolerability for these approaches. Because the source characterizes the findings as preliminary, they represent an emerging treatment direction rather than an established conclusion.
The HLH-2004 protocol recommends initial treatment with dexamethasone and etoposide for four weeks in EBV-related cases. Etoposide induces apoptosis, limits inflammatory cytokine release, and inhibits EBV nuclear antigen synthesis and infected cell transformation. Rituximab may also be beneficial, as the virus primarily replicates in B cells.
Prompt treatment is crucial for survival, but HLH remains a challenging condition with high mortality rates. Neurological symptoms and persistently high ferritin levels worsen the prognosis, emphasizing the need for heightened awareness and rapid intervention.